A Study of LP-118 in Patients with Advanced Tumors

Phase 1

Active, not recruiting

• Conditions: Lymphoma, Non-Hodgkin; Solid Tumor
• Interventions: Drug: LP-118 tablet

• Registration Number: NCT05025358
• Lead Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD.

Brief Summary

This is a phase I, multi-center, open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-118 in patients with advanced malignancies, including solid tumors and lymphomas. LP-118 is a BCL-2/BCL-XL small molecule inhibitor.

Detailed Description

LP-118 is an oral selective BCL-2 inhibitor with tuned BCL-XL activity, aiming to improve antitumor efficacy and reduce the risk of thrombocytopenia. Clinical development of LP-118 includes targeting of relapsed or refractory hematological malignancies and solid tumors. This is a multi-center, open-label, Phase 1 dose escalation study of LP-118 in patients with advanced malignancies, including advanced/metastatic solid tumors and relapsed/refractory B cell, T/NK cell lymphomas, to determine the safety, tolerability, pharmacokinetics profile and preliminary anti-tumor efficacy. Upon completion of the Phase 1 dose escalation study and establishment of maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), the dose expansion study will be implemented in patients with protocol designated type of disease.

Study Timeline

• Study First Submitted: 2021-07-30
• Study First Submitted QC: 2021-08-25
• Study First Posted: 2021-08-27
• Study Start: 2021-09-14
• Status Verified: 2024-09
• Last Update Submitted: 2024-09-27
• Last Update Posted: 2024-09-30
• Primary Completion: 2025-01-30
• Study Completion: 2025-12-30

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 96

Inclusion Criteria

• Subjects with histologically or cytologically confirmed malignancy, including either of the following disease: relapsed or refractory lymphomas with at least one measurable disease based on Lugano 2014 criteria; or advanced or metastatic solid tumors based on RECIST V1.1 criteria.
• Subjects have a life expectancy of ≥12 weeks, and Eastern Cooperative Oncology Group (ECOG) performance score less than or equal to 1.
• Subjects must have adequate bone marrow function independent of blood transfusion or growth factor support per local laboratory reference range at Screening.
• Subjects must have adequate coagulation, renal, and hepatic function, per local laboratory reference range at Screening.
• All acute toxicity from previous anti-tumor treatment or surgery has been alleviated to NCI CTCAE 5.0 ≤ Grade 1.
• All enrolled subjects should take medically approved contraceptives during the entire treatment period and within 90 days after the end of treatment.
• Volunteer and sign informed consent, willing to follow trial protocol.

Read More

Exclusion Criteria

• Subjects who have undergone allogeneic or autologous hematopoietic stem cell transplantation or CAR-T cell therapy (except for lymphoma patients who had received autologous stem cell transplantation or CAR-T cell therapy before 90 days of the first dose of LP-118).

• Subjects who have received the following treatments within 4 weeks or 5 half-lives before the first dose of study drug:

  • Antitumor therapies including myelosuppressive chemotherapy, targeted therapy, biological therapy and/or immunotherapy;
  • Any investigational treatment;
  • Patients who have undergone major surgery, severe trauma or radiotherapy.

• Subjects who have received the following treatments within 1 week before the first dose of study drug:

  • Steroids or traditional herbal medicine for antitumor purposes;
  • Strong and moderate CYP3A inhibitors and inducers, grapefruit and grapefruit juice;
  • Any medications that can cause QTc interval prolongation or torsional tachycardia.

• Solid tumor patients with ITP or AIHA.

• Subjects with known bleeding disease or with a history of non-chemotherapy induced thrombocytopenic bleeding or ineffective platelet transfusion within 1 year before the first dose of study drug.

• Subjects with uncontrollable or CTCAE ≥ grade 2 gastrointestinal bleeding occurred within 90 days before the first dose of study drug.

• Subjects have received the therapeutic dose of anticoagulant or antiplatelet drugs within 1 week before the first dose of study drug.

• Subjects have any serious and/or uncontrolled systemic disease.

• Subjects have poor cardiovascular function, in line with New York Heart Association (NYHA) cardiac function classification ≥ 2 or QTcF greater than 450ms (male) or 470ms (female) on ≥ 3 independent ECG.

• Subjects have disease states where clinical manifestations may be difficult to control, including but not limited to HIV, HBV, HCV, syphilis positive or active bacterial and fungal infections.

• Lymphoma with primary central nervous system (CNS) malignancy or any disease affects the CNS.

• Any gastrointestinal conditions that may severely affect the study drug absorption or pharmacokinetic parameters.

• Subjects who have known severe allergies to study drugs or any excipients.

• Subjects who have evidence of a second primary tumor.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
LP-118	LP-118 tablet	The classic "3+3" design at dose levels of 50mg, 100mg, 200mg, 300mg, 400mg and 500mg will be implemented in this study.

Primary Outcome Measures

Name	Time	Method
Recommended phase II dose (RP2D)	Up to 24 months	The safe dose that demonstrates the greatest pharmacological activity.
PK evaluation of area under the plasma concentration versus time curve (AUC) of LP-118	Up to Cycle 6 (each cycle is 28 days)	AUC indicates the extent of exposure to LP-118 and its clearance rate from the body.
PK evaluation of time to maximum concentration (Tmax) of LP-118	Up to Cycle 6 (each cycle is 28 days)	Tmax indicates the time taken to reach the maximum drug concentration (i.e. Cmax).
Maximum tolerated dose (MTD)	Up to 24 months	The highest dose that does not cause unacceptable side effects or overt toxicities which will be assessed by NCI CTCAE v5.0.
PK evaluation of peak plasma concentration (Cmax) of LP-118	Up to Cycle 6 (each cycle is 28 days)	Cmax indicates the highest drug concentration in the blood after LP-118 administration.
Adverse events	Up to 24 months	The incidence and severity of adverse events as assessed by NCI CTCAE v5.0.

Secondary Outcome Measures

Name	Time	Method
Progression-free survival (PFS)	Up to 24 months	The time from first dose to disease progression or death, whichever occurs first.
Duration of response (DOR)	Up to 24 months	The time from first documented response to disease progression or death.
Overall response rate (ORR)	Up to 24 months	The proportion of patients who have a partial or complete response after LP-118 treatment.
Overall survival	Up to 24 months	The time from first dose to the date of death from any cause.

Trial Locations

Locations (4)

Guangdong Provincial People's Hospital; 🇨🇳 Guangzhou, Guangdong, China

The First Affiliated Hospital of Jinan University; 🇨🇳 Guangzhou, Guangdong, China

Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology; 🇨🇳 Wuhan, Hubei, China

First Affiliated Hospital of Zhejiang University School of Medicine; 🇨🇳 Hangzhou, Zhejiang, China